CR Shuanghe has partnered with U.S. pharmaceutical companies to develop oral small molecule anti-COVID-19 drugs

Recently, CR Shuanghe and The American Lind Pharmaceutical Company reached an agreement to jointly develop an oral small molecule RNA polymerase inhibitor drug for the treatment of novel coronavirus pneumonia COVID-19, which uses Lind's BEPro technology, and CR Shuanghe will have the exclusive development and commercialization rights of this drug in major asian regions in the future. The project is the second cross-border innovative drug project of CrUs Shuanghe since the beginning of the year, which is still in the pre-clinical research stage.

BEPro technology is the latest generation of prodrug technology developed by Ligand for improving the oral administration of nucleoside antivirals. The antiviral drugs developed by BEPro technology have the characteristics of good oral bioavailability and increased drug concentration in the lungs, which have potential clinical therapeutic value for the development of small molecule oral COVID-19 therapeutic drugs.